Evidence map›Paper›PMID 40109823›Full record

ArticleCureus2025

Seronegative Autoimmune Hepatitis Following Coronavirus Disease 2019 (COVID-19) Infection.

Mohammad Kloub, Khaled A Elfert, Flor Rosado, Ahmed Elnajjar, Mohamed Eldesouki, Abdul-Rahman I Abusalim

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mohammad KloubDepartment of Internal Medicine, Saint Michael's Medical Center, New York Medical College, Newark, USA.
Khaled A ElfertDepartment of Internal Medicine, St. Barnabas Hospital Health System, New York, USA.
Flor RosadoDepartment of Internal Medicine, St. Barnabas Hospital Health System, New York, USA.
Ahmed ElnajjarDepartment of Gastroenterology, Al-Shifa Hospital, Gaza, PSE.
Mohamed EldesoukiDepartment of Internal Medicine, Saint Michael's Medical Center, New York Medical College, Newark, USA.
Abdul-Rahman I AbusalimDepartment of Internal Medicine, University of Wisconsin School of Medicine and Public Health, Madison, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autoimmune hepatitis is an autoimmune liver condition of uncertain etiology. Environmental triggers have been involved in the pathophysiology of the disease. The triggers include viruses, immunizations, and drugs. Since the emergence of the coronavirus disease 2019 (COVID-19) pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been implicated in the development of various autoimmune diseases. We report the case of a 58-year-old patient who had persistent elevation in liver transaminase levels after COVID-19 infection. After undergoing a liver biopsy, he was diagnosed with seronegative autoimmune hepatitis with an excellent response to steroids. Our case highlights the importance of considering the diagnosis of autoimmune hepatitis in patients with persistent elevation of liver transaminases after COVID-19 infection.

Indexed as

autoimmune hepatitis (aih)case reportclinical autoimmunitycovid-19 infectionmolecular mimicry

Identifiers

PMID40109823
PMCPMC11920853

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.